Compare RCON & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCON | CNSY |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 20.6M |
| IPO Year | 2008 | 2016 |
| Metric | RCON | CNSY |
|---|---|---|
| Price | $0.90 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $27.75 |
| AVG Volume (30 Days) | 113.0K | ★ 161.9K |
| Earning Date | 09-30-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,430,788.00 | $5,213,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.08 | $414.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.02 | $1.49 |
| 52 Week High | $6.42 | $4.03 |
| Indicator | RCON | CNSY |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 38.01 |
| Support Level | $0.79 | $1.54 |
| Resistance Level | $1.04 | $1.96 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 13.29 | 26.19 |
Recon Technology Ltd provides automation systems, industrial equipment, and support services tailored for the oil and gas industry in China. The company's business spans key segments such as automation products and software, equipment and accessories, oilfield environmental protection, and platform outsourcing services. It generates the majority of its revenue by providing integrated automation services to Chinese petroleum companies at oilfields. Its key products and services include pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system. The company's operations are centered on servicing upstream clients throughout China, with some broader industrial automation solutions.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.